# Mitochondrial Unification: Divergence Analysis

**Source run**: `evo_20260210_232635_neuroscience`
**Extraction date**: 2026-02-11
**S3 outcome**: FAILED after 3 cycles (cosine 0.736, TYPE 0/1 35.29%)
**Question**: "What role does mitochondrial dysfunction play in the shared pathophysiology of neurodegeneration (Alzheimer's, Parkinson's) and metabolic disease (type 2 diabetes), and what molecular targets link these conditions through a common mitochondrial vulnerability?"

## Why It Failed

This question asks about a **genuinely unsettled scientific question**. The models agreed on individual mechanisms but diverged on which mechanism is *primary*. Unlike the pharmacology questions (CBD, lithium, THC) where there's a clear molecular target, mitochondrial unification has no single gateway receptor — it's a systems-level question.

TYPE distribution tells the story:
- TYPE 0: 0% (no claim achieved 5/5 agreement)
- TYPE 1: 35% (some overlap, but not enough)
- TYPE 2: 35% (many claims only 2/5)
- TYPE 3: 29% (nearly a third were singulars)

## What the Models Proposed (independently)

### Points of Partial Convergence

**Delta-p collapse as integrative variable** (Claude + Mistral)
- Proton motive force (delta-psi + delta-pH) simultaneously governs ATP synthesis, ROS directionality, and Ca2+ uptake via MCU
- If delta-p is the shared output, then different inputs (amyloid, alpha-synuclein, glucolipotoxicity) converge on the same bioenergetic failure mode

**CypD-mediated mPTP as terminal event** (Claude + Mistral)
- Cyclophilin D lowers Ca2+ threshold for mPTP opening
- Ca2+ threshold: ~50-100 uM in disease vs ~200-300 uM in healthy
- Final common pathway: excitotoxicity (AD/PD) and glucolipotoxicity (T2D) both converge on mPTP

**Miro/Milton/TRAK trafficking disruption** (Claude + Mistral)
- Mitochondrial motility defects precede gross bioenergetic failure
- Affects both neurons (axonal transport) and beta-cells (process maintenance)

**PINK1/Parkin mitophagy** (broad agreement but TYPE 1 only)
- Rate-limiting for mitochondrial quality control
- Failure precedes bioenergetic collapse by years

**BBB exclusion of mitochondrial therapeutics** (Claude + Mistral + Grok)
- MitoQ (680 Da) exceeds 400 Da passive diffusion cutoff
- Explains why mito-targeted antioxidants work peripherally (T2D) but fail in CNS (AD/PD)

### Where They Diverged

The models couldn't agree on hierarchy. Each proposed a different "master variable":
- Claude: delta-p collapse as integrative variable
- Mistral: CypD-mPTP as terminal event
- Grok: BBB exclusion as explanatory framework for therapeutic failure
- Gemini/DeepSeek: proposed competing mechanisms without clear convergence

## Significance

This is a **legitimate negative result**. The framework correctly identified that mitochondrial unification is an open question where reasonable scientific models disagree. Compare to:
- CBD (cosine 0.908, TYPE 0/1 82%): Clear molecular target, well-characterized pathway
- Lithium (cosine 0.917, TYPE 0/1 95%): Clear molecular targets (GSK-3beta, IMPase)
- THC (failed S3 but rich gold): Clear molecular target (CB1), open question is about dose-pathway mapping

The mitochondrial question lacks a single gateway target — and the pipeline correctly reflected this.

## Pipeline Stats
- Total LLM calls: 15 (3 cycles x 5 models)
- S3 failed: cosine 0.736, TYPE 0/1 35.29%
- 17 unique claims, mostly singulars and TYPE 2
